The unsatisfactory therapeutic effect and long-term adverse effect markedly prevent inorganic nanomaterials from clinical transformation. In light of this, we developed a novel biodegradable theranostic agent (MnCO 3 :Ho 3+ @DOX/Ca 3 (PO 4 ) 2 @BSA, HMCDB) based on the sonosensitizer manganese carbonate (MnCO 3 ) coating with calcium phosphate (Ca 3 (PO 4 ) 2 ) and simultaneously loaded it with the chemotherapeutic drug doxorubicin (DOX). Due to the mild acidity of the tumor microenvironment (TME), the Ca 3 (PO 4 ) 2 shell degraded first, releasing substantial quantities of calcium ions (Ca 2+ ) and DOX. Meanwhile, with the ultrasound (US) irradiation, MnCO 3 produced enough reactive oxygen species (ROS) to cause oxidative stress in the cells, resulting in accumulation of Ca 2+ . Consequently, the cascade effect significantly amplified the therapeutic effect. Importantly, the nanocomposite can be completely degraded and cleared from the body, demonstrating that it was a promising theranostic agent for tumor therapy. Furthermore, the doped holmium ions (Ho 3+ ) and in situ generation of manganese ions (Mn 2+ ) in TME endow the nanoagent with the ability for tumor-specific bimodality T 1 /T 2 -weighted magnetic resonance imaging (MRI). This novel nanoplatform with low toxicity and biodegradability holds great potential for cancer diagnosis and treatment.